Haematologica 2003 - Supplements
Haematologica 2003 - Supplements
Haematologica 2003 - Supplements
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
of genes, one of them being the gene for transmembrane protein<br />
carbonic anhydrase isoenzyme IX (CA IX) which is involved in<br />
maintaining the acid-base balance of the cell. Since the degree of<br />
intratumoral hypoxia is positively correlated with HIF 1, the<br />
expression of CA IX has been proven an indirect parameter for<br />
the degree of tissue hypoxia.<br />
Aim of the study: Determining the expression of CA IX, the<br />
endothelial cell proliferation fraction (ECP) and mean vessel density<br />
(MVD) of bone marrow (BM) biopsies in non-neoplastic diseases,<br />
haematological malignancies and metastatic carcinomas.<br />
Materials and methods: BM biopsies were included at the time of<br />
diagnosis before any treatment was administered from 12 patients<br />
without malignancies (NON-NEO), 17 patients with MGUS, 23<br />
myeloma patients (MM), 44 patients with a chronic<br />
myeloproliferative syndrome (CMPS), 13 patients with a CD34-<br />
negative AML, 15 patients with a CLL, 25 patients with a bone<br />
marrow metastasis of an epithelial tumour (META).<br />
The BM biopsies were immunostained with anti-CA IX. The<br />
endothelial cell proliferation was determined by a double staining<br />
for CD34 and Ki-67. The mean vessel density (MVD), the<br />
number of vessels per 0.22 mm2 was determined on sections<br />
immunostained for CD34.<br />
Results: 7 of 25 META had at least a focal membranous<br />
expression of CA IX whereas no expression was observed in all<br />
haematological neoplasms nor in MGUS and bone marrows of<br />
NON-NEO patients. There was a significantly (Kruskal Wallis: p<br />
< 0,0001) increased MVD in MM (19.1(11.3), META (24.0(7.7),<br />
CMPS (19,2(7,6), AML (20,8(6,8) compared to the NON-NEO<br />
(8.6(6.5) cases. There was no significant difference for MGUS<br />
(7.3(3.5) and CLL (9,2(4,6) compared to NON-NEO (p>0,05).<br />
The MM (1.9(2.0), CMPS (0,9+0,8), AML(1,2(1,1) and the<br />
META (2.5(1.4) had a significantly increased ECP compared to<br />
the the NON-NEO(0.1(0.3) cases. For the CLL (0,1(1,3) and the<br />
MGUS (0.0(0.0) no significant difference could be demonstrated.<br />
A significant difference in ECP was observed between MM and<br />
MGUS. The intensity of CD34 staining was graded: grade 1<br />
corresponded to a weak to partially negative staining of the<br />
majority of the (sinusoidal) vessels. Grade 2 was attributed to the<br />
cases in which part of the vessels had a weak to partially negative<br />
staining and part of the vessels had a strong CD34 staining and<br />
grade 3 if the majority were strongly staining for CD34 (small<br />
sprouting vessels). MM with a diffuse growth pattern (7 cases)<br />
had grade 3 staining vessels; in the interstitial-nodular growth<br />
pattern (5 cases), 2 were grade 1, 2 were grade 2 and 1 was grade<br />
1 and in the pure interstitial pattern (9), eight had grade 1 and 1<br />
had grade 3 (chi-squared p-value= 0.0003).<br />
In MM there was a significant correlation between the tumorload<br />
and the MVD (r=0.72, =0.0001), between the tumorload and the<br />
endothelial cell proliferation (r=0.60, p=0.03) and between the<br />
MVD and the endothelial cell proliferation (r=0.60, p=0.009)<br />
6.3 Bone disease<br />
148<br />
Role of myeloma-induced osteoclastogenesis in the<br />
disease.<br />
Shmuel Yaccoby, John Shaughnessy, Fenghuang Zhan,<br />
Qing Yi, Bart Barlogie, and Joshua Epstein.<br />
Myeloma Institute for Research and Therapy, Arkansas Cancer<br />
Research Center, University of Arkansas for Medical Sciences,<br />
Little Rock, Arkansas, USA.<br />
We have studied the role of myeloma-induced osteoclastogenesis<br />
in the disease process. Initially, we determined whether myeloma<br />
plasma cells (MM PC) could induce osteoclastogenesis in a<br />
stromal cell-free environment. Next, we examined the effect of<br />
osteoclasts (OC) on the growth and survival of myeloma and<br />
healthy donor PC, and the molecular consequences of PC<br />
interactions with OC.<br />
Cultures of osteoclast precursors (pOC) and mature active<br />
multinucleated OC were prepared from PBSCs and MNC from 5<br />
healthy donors and PBSCs from 30 myeloma patients. CD138-<br />
enriched PC were purified from BM aspirates from 50 patients<br />
and from 6 healthy donors (NPC).<br />
MM PC conditioned media from 9 patients increased migration<br />
of pOC across a 5 µM pore size membrane 1.6-4.2 fold from<br />
127±37 (mean±SEM) in controls (p=0.01). In co-cultures with<br />
pOC, MM PC from 22 patients induced formation of<br />
multinucleated, bone-resorbing OC by 6 fold from 50±8 in<br />
controls (p